Covered recipient · General Payments record
EMMALIND APONTE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$783.98
11 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $736.96 | 9 |
| Education | $47.02 | 2 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | $136.33 | 2 |
| AstraZeneca Pharmaceuticals LP | $124.99 | 1 |
| Bayer Healthcare Pharmaceuticals Inc. | $124.99 | 1 |
| Genmab U.S., Inc. | $124.99 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $99.71 | 1 |
| GENZYME CORPORATION | $85.65 | 1 |
| E.R. Squibb & Sons, L.L.C. | $40.30 | 2 |
| Alexion Pharmaceuticals, Inc. | $30.00 | 1 |
| Regeneron Healthcare Solutions, Inc. | $17.02 | 1 |
Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
EMMALIND APONTE
NPI 1699985002 · CMS profile ID 895385
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SAN ANTONIO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1699985002?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699985002?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699985002?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1699985002?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
11 matching records · $783.98 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–11 of 11.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Myriad Genetic Laboratories, Inc. | $117.44 | 12/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152526702 | CMS |
| Regeneron Healthcare Solutions, Inc. | $17.02 | 11/15/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114000589 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.99 | 10/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104783152 | CMS |
| Genmab U.S., Inc. | $124.99 | 09/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126826372 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $124.99 | 07/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086115280 | CMS |
| Alexion Pharmaceuticals, Inc. | $30.00 | 07/02/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1094015266 | CMS |
| Myriad Genetic Laboratories, Inc. | $18.89 | 05/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152526700 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.05 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101272273 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $99.71 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144952881 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.25 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101272253 | CMS |
| GENZYME CORPORATION | $85.65 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139759930 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $813,810.23 | 86 |
| PY2024 | Principal investigator | $353,805.35 | 318 |
| PY2023 | Principal investigator | $781,091.71 | 185 |
| PY2022 | Principal investigator | $668,992.46 | 76 |
| PY2021 | Principal investigator | $746,317.94 | 121 |
| PY2020 | Principal investigator | $559,338.29 | 124 |
| PY2019 | Recipient | $1,341.00 | 1 |
| PY2019 | Principal investigator | $441,514.52 | 20 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
76 records in PY2022
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,511.97 | 12/31/2022 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | Trastuzumab deruxtecan with pertuzumab-matching placebo | No dispute reported | 06/30/2026 | 914597777 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,967.56 | 12/31/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY SOUTHWEST FORT WORTH | Trastuzumab deruxtecan with pertuzumab-matching placebo | No dispute reported | 06/30/2026 | 914601161 |
| Principal investigator 1 | Genentech, Inc. | $17,396.00 | 12/21/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | No dispute reported | 06/30/2026 | 950692435 |
| Principal investigator 1 | Genentech, Inc. | $70,428.00 | 12/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 950692253 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 12/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856457 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 12/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856469 |
| Principal investigator 1 | Genentech, Inc. | $10,583.00 | 12/14/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | No dispute reported | 06/30/2026 | 950692441 |
| Principal investigator 1 | Genentech, Inc. | $2,556.00 | 12/14/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | No dispute reported | 06/30/2026 | 950692445 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,398.00 | 12/12/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 965505303 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,505.00 | 11/17/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 943950007 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,500.00 | 11/03/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 943950001 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,125.00 | 11/02/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 943950005 |
| Principal investigator 1 | Genentech, Inc. | $89,741.00 | 10/28/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | No dispute reported | 06/30/2026 | 950704761 |
| Principal investigator 1 | ViiV Healthcare Company | $1,125.00 | 10/26/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 943806653 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 10/21/2022 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 950641271 |
| Principal investigator 1 | Genentech, Inc. | $7,964.00 | 10/19/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | No dispute reported | 06/30/2026 | 950704767 |
| Principal investigator 1 | Seagen Inc. | $765.00 | 10/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer | No dispute reported | 06/30/2026 | 917856435 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 10/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856485 |
| Principal investigator 1 | ViiV Healthcare Company | $7,000.00 | 10/14/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 943806647 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,398.00 | 09/19/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 943949997 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,500.00 | 09/16/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | No dispute reported | 06/30/2026 | 950716477 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,500.00 | 09/16/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | No dispute reported | 06/30/2026 | 950716483 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 09/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856369 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,125.00 | 09/06/2022 | Non-covered Recipient Entity US Oncology Research LLC Attn Accounts Receivable | A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease | No dispute reported | 06/30/2026 | 935584757 |
| Principal investigator 1 | Genentech, Inc. | $9,500.00 | 09/01/2022 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 950649271 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 08/30/2022 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 950649725 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 08/30/2022 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 950649763 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 08/30/2022 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 950649793 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,398.00 | 08/24/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 943950003 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 08/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856357 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,398.00 | 08/02/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 943949999 |
| Principal investigator 1 | Seagen Inc. | $765.00 | 07/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer | No dispute reported | 06/30/2026 | 917856319 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 07/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856351 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 07/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856411 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $26,104.25 | 07/08/2022 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | Trastuzumab deruxtecan with pertuzumab-matching placebo | No dispute reported | 06/30/2026 | 914590751 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,796.00 | 06/28/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 943949995 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,500.00 | 06/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY SOUTHWEST FORT WORTH | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 914598889 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $10,000.00 | 06/15/2022 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 914599733 |
| Principal investigator 1 | Genentech, Inc. | $52,190.25 | 06/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 950729297 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 05/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856093 |
| Principal investigator 1 | Seagen Inc. | $1,841.00 | 05/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856101 |
| Principal investigator 1 | Seagen Inc. | $1,280.00 | 05/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856107 |
| Principal investigator 1 | Seagen Inc. | $2,000.00 | 05/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856111 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 05/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856255 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,125.00 | 05/03/2022 | Non-covered Recipient Entity US Oncology Research LLC Attn Accounts Receivable | A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease | No dispute reported | 06/30/2026 | 935582941 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $970.00 | 04/15/2022 | Non-covered Recipient Entity CANCER CARE NETWORK S TEXAS | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH ADVANCED TRIPLE NEGATIVE BREAST CANCER WITH EITHER PHOSPHOINOSITIDE-3- | No dispute reported | 06/30/2026 | 909392905 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 04/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856071 |
| Principal investigator 1 | Seagen Inc. | $2,150.00 | 04/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856081 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 04/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856197 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 04/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856213 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 04/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856219 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 04/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856225 |
| Principal investigator 1 | Seagen Inc. | $295.00 | 04/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856231 |
| Principal investigator 1 | Seagen Inc. | $3,430.00 | 03/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917855449 |
| Principal investigator 1 | Seagen Inc. | $2,150.00 | 03/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856047 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,000.00 | 03/09/2022 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer | No dispute reported | 06/30/2026 | 914595107 |
| Principal investigator 1 | Seagen Inc. | $8,990.00 | 03/07/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856277 |
| Principal investigator 1 | Seagen Inc. | $8,990.00 | 03/07/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856301 |
| Principal investigator 1 | Genentech, Inc. | $6,000.00 | 02/25/2022 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 950682571 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $38,332.00 | 02/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY SOUTHWEST FORT WORTH | Trastuzumab deruxtecan with pertuzumab-matching placebo | No dispute reported | 06/30/2026 | 914595419 |
| Principal investigator 1 | Seagen Inc. | $2,150.00 | 02/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917855431 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,125.00 | 02/14/2022 | Non-covered Recipient Entity US Oncology Research LLC Attn Accounts Receivable | A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease | No dispute reported | 06/30/2026 | 935583399 |
| Principal investigator 1 | Seagen Inc. | $8,990.00 | 02/14/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856271 |
| Principal investigator 1 | Seagen Inc. | $8,990.00 | 02/14/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856295 |
| Principal investigator 1 | Seagen Inc. | $8,990.00 | 01/31/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856265 |
| Principal investigator 1 | Seagen Inc. | $8,990.00 | 01/31/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856289 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,928.43 | 01/28/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY | EPIK-B2: A TWO PART, PHASE III, MULTICENTER, RANDOMIZED (1:1), DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH HER2-POSIT | No dispute reported | 06/30/2026 | 909418059 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $112,449.00 | 01/19/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH | A PHASE II MULTICENTER OPEN LABEL TWO COHORT NON COMPARATIVE STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB PLUS FULVESTRANT OR LETROZOLE IN PATIENTS WITH PIK3CA MUTANT HORMONE RECEPTOR HR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER ABC WHO HAVE P | No dispute reported | 06/30/2026 | 909425937 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,400.00 | 01/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY SOUTHWEST FORT WORTH | A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer | No dispute reported | 06/30/2026 | 914595003 |
| Principal investigator 1 | Eli Lilly and Company | $15,514.00 | 01/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 917841625 |
| Principal investigator 1 | Eli Lilly and Company | $3,824.00 | 01/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | No dispute reported | 06/30/2026 | 917844105 |
| Principal investigator 1 | Seagen Inc. | $2,150.00 | 01/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917855395 |
| Principal investigator 1 | Seagen Inc. | $2,150.00 | 01/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917855489 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 01/15/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917855495 |
| Principal investigator 1 | Seagen Inc. | $8,990.00 | 01/04/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856259 |
| Principal investigator 1 | Seagen Inc. | $8,990.00 | 01/04/2022 | Non-covered Recipient Entity TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | No dispute reported | 06/30/2026 | 917856283 |